Based on a review of published Phase 3 trials, patients with previously treated multiple myeloma who stopped responding to Revlimid (lenalidomide) showed significant improvement in progression-free survival when treated with SARCLISA in combination with Kyprolis (carfilzomib) and dexamethasone (Kd), compared to treatment with Kd alone. At a median follow-up of 44 months, the median progression-free survival was 41.7 months for the SARCLISA + Kd group versus 20.8 months for the Kd alone group. Additionally, 56% of patients in the SARCLISA + Kd group were living progression-free at the time of analysis, compared to 45% in the Kd alone group. An earlier analysis at a median follow-up of 20.7 months showed even more pronounced benefits, with 74% of patients in the SARCLISA + Kd group living progression-free compared to 59% in the Kd alone group. It's important to note that direct comparisons between different trials cannot be made due to variations in patient populations, treatment mechanisms, and administration methods, all of which can influence trial outcomes. Patients are encouraged to discuss these findings with their healthcare provider.
Significant Improvement in Progression-Free Survival with SARCLISA Combination Therapy for Previously Treated Multiple Myeloma
A Phase 3 trial reveals that patients with previously treated multiple myeloma who stopped responding to Revlimid experienced a median progression-free survival of 41.7 months with SARCLISA combined with Kyprolis and dexamethasone, compared to 20.8 months with Kyprolis and dexamethasone alone.
Reference News
Previously Treated Trial Results
Phase 3 trials show SARCLISA + Kyprolis and dexamethasone (Kd) improved progression-free survival in previously treated multiple myeloma patients, with 41.7 months median vs 20.8 months for Kd alone. At 44 months, 56% on SARCLISA + Kd vs 45% on Kd alone remained progression-free. Earlier, at 20.7 months, 74% vs 59% were progression-free.